More than $75,000 at Stake in Reclast Injury Suit

Reclast manufacturer Novartis Pharmaceuticals Corp. established that the federal jurisdiction threshold of more than $75,000 was at stake in a plaintiff’s personal injury suit over the bone-building drug, the U.S. District Court for the Northern District of Alabama held July 2 (Jones v. Novartis Pharmaceuticals Corp., N.D. Ala., No. 13-624).

Ernesteen Jones received Reclast injections to treat osteoporosis. Jones sued Novartis in an Alabama state court, alleging she suffered femur fractures and other injuries. Her complaint did not specify the monetary amount sought. Novartis removed the suit to federal court based on diversity jurisdiction, prompting the plaintiff to ...